Aldeyra Therapeutics, Inc.
Compositions and methods of treating retinal disease

Last updated:

Abstract:

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Status:
Grant
Type:

Utility

Filling date:

7 Jan 2019

Issue date:

9 Feb 2021